VaxGen Receives Repayment in Full of Bridge Loan to Raven biotechnologies

Friday, July 18, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

SOUTH SAN FRANCISCO, Calif., July 17 VaxGen,Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, today announcedthat it has received repayment in full, including accrued interest, of thebridge loan it extended to Raven biotechnologies Inc. in connection with theproposed merger between the two companies. The proposed merger was terminatedby mutual consent in March 2008. The total amount received from Raven inrepayment was $6.27 million.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco,California. The company owns a state-of-the-art biopharmaceuticalmanufacturing facility with a 1,000-liter bioreactor that can be used to makecell culture or microbial biologic products. For more information, pleasevisit the company's web site at http://www.vaxgen.com.

SOURCE VaxGen, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook